We are experiencing technical difficulties. Your form submission has not been successful. Please accept our apologies and try again later. Details: [details]
We are experiencing technical difficulties. Your form submission has not been successful. Please accept our apologies and try again later. Details: [details]
Fill in your details below and get direct access to content on this page
We are experiencing technical difficulties. Your form submission has not been successful. Please accept our apologies and try again later. Details: [details]
We are experiencing technical difficulties. Your form submission has not been successful. Please accept our apologies and try again later. Details: [details]
AJ Vaccines implements a prototype of vision-based vial counting
To further strengthen data integrity at vaccine manufacturer AJ Vaccines, OMRON has successfully developed and deployed a proof of concept for the automatic counting of vials in AJ Vaccines’ production.
Key Benefits
100% success rate in vial counting for reliable quality control.
Automated data reconciliation enhances production transparency.
Retrofit solution avoids costly production line replacements.
GxP-compliant-ready system meets life sciences standards.
Supports scalable, digitized production processes for the future.
At a Glance
AJ Vaccines has implemented a successful proof of concept OMRON to automate vial counting using the advanced FH vision system. This solution improves data integrity, enhances quality control, and supports regulatory compliance, all while avoiding the need for major production line changes. With a 100% success rate during testing, the system has demonstrated its reliability and ease of use. Fully aligned with life sciences standards, it helps AJ Vaccines take the next step toward scalable, cost-efficient digitization of their manufacturing processes — paving the way for increased efficiency and transparency in vaccine production.
AJ Vaccines develops and manufactures vaccines, diagnostics, and therapeutic solutions and has a close collaboration with both WHO and UNICEF. Established in 2017 following the acquisition of the vaccine division of Statens Serum Institut, the company continues a legacy of over 100 years in vaccine manufacturing. In its headquarters and main production facility in Copenhagen, the company produces vaccines for diseases such as diphtheria, tetanus, pertussis, tuberculosis, and polio.
“
“As an innovative company, we want to be at the forefront of the technological frontier by trying out new, innovative solutions that can increase our high-quality standards even further.”
